ArticleHealth science reports2026
Identifying High-Risk Medications for Drug-Induced Dystonia: A 20-Year Retrospective Real-World Pharmacovigilance Study Based on FAERS.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identifying High-Risk Medications for Drug-Induced Dystonia: A 20-Year Retrospective Real-World Pharmacovigilance Study Based on FAERS.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Drug-induced dystonia is a serious, potentially disabling adverse event (AE) associated with certain medications. Despite its clinical relevance, the existing literature is largely limited to case reports or analyses of individual drugs, and a systematic evaluation of medications implicated in dystonia remains lacking. This study undertook one of the first comprehensive screenings and risk signal rankings of drugs linked to dystonia using data from the FDA adverse event reporting system (FAERS), aiming to inform clinical drug safety. Methods: Reports of dystonia-related AEs from Q1 2004 to Q3 2024 were retrieved from FAERS using standardized MedDRA queries. Disproportionality analyses were conducted using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS) methods to identify potential drug-dystonia signals. The Kaplan-Meier method was applied to assess the time to dystonia onset after drug exposure. Sensitivity analyses using the Results: A total of 27,618 patients with 28,938 dystonia reports were included. Metoclopramide (7178 reports) and aripiprazole (1595 reports) were most frequently reported. Among the top 50 drugs, metoclopramide showed the strongest disproportionality signal, followed by prochlorperazine and haloperidol. Notably, dystonia was not listed in the package inserts of eight identified drugs, including certain antiepileptics, antidepressants, and antiparkinsonian agents. Most events occurred within 0-30 days of drug initiation. The combination of aripiprazole and risperidone was frequently reported and showed notable interaction signals. Conclusions: Metoclopramide and several antipsychotics were strongly associated with reported drug-induced dystonia. These findings highlight the need for cautious prescribing and close monitoring, particularly with antipsychotic combinations, and may support improved risk awareness and labeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.